

Statement from Dana-Farber Cancer Institute

With support from federal funding, Dana-Farber Cancer Institute has helped lead major advances in cancer research. Continued progress depends on a research system grounded in expert review, collaboration, and stability. Because cancer research often takes years and relies on clinical trials and long-term follow-up, changes to federal grant processes can affect the pace, continuity, and impact of this work.

Dana-Farber is concerned that the White House Office of Management and Budget's proposed federal grant rule could disrupt that system, slowing research progress and making it more difficult to develop new treatments for patients. Research advances are best supported by a funding environment that is predictable, fair, and informed by scientific expertise.

Dana-Farber submitted formal comments on the proposed rule and plans to work with others across the cancer and biomedical research community to provide feedback on the rule's potential effects on research, clinical trials, and patient care.